87 related articles for article (PubMed ID: 15648949)
21. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
22. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
23. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
24. Capitalizing on the immunogenicity of dying tumor cells.
Fonseca C; Dranoff G
Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
[TBL] [Abstract][Full Text] [Related]
25. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
Kassouf N; Thornhill MH
Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
[TBL] [Abstract][Full Text] [Related]
26. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
[TBL] [Abstract][Full Text] [Related]
27. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.
Liang M; Yang H; Fu J
Cancer Lett; 2009 Apr; 276(1):47-52. PubMed ID: 19046800
[TBL] [Abstract][Full Text] [Related]
28. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
29. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
30. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
32. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
Ferris RL; Whiteside TL; Ferrone S
Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
[TBL] [Abstract][Full Text] [Related]
33. Porcine PD-L1: cloning, characterization, and implications during xenotransplantation.
Jeon DH; Oh K; Oh BC; Nam DH; Kim CH; Park HB; Cho J; Lee JR; Lee DS; Lee G
Xenotransplantation; 2007 May; 14(3):236-42. PubMed ID: 17489864
[TBL] [Abstract][Full Text] [Related]
34. Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism.
Baleeiro RB; Barbuto JA
Mol Immunol; 2008 Jul; 45(12):3502-4. PubMed ID: 18513799
[TBL] [Abstract][Full Text] [Related]
35. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
36. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance.
Berg M; Wingender G; Djandji D; Hegenbarth S; Momburg F; Hämmerling G; Limmer A; Knolle P
Eur J Immunol; 2006 Nov; 36(11):2960-70. PubMed ID: 17039564
[TBL] [Abstract][Full Text] [Related]
37. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
38. Modulation of cancer-specific immune responses by amino acid degrading enzymes.
Timosenko E; Hadjinicolaou AV; Cerundolo V
Immunotherapy; 2017 Jan; 9(1):83-97. PubMed ID: 28000524
[TBL] [Abstract][Full Text] [Related]
39. The clinical implications of antitumor immunity in head and neck cancer.
Allen CT; Judd NP; Bui JD; Uppaluri R
Laryngoscope; 2012 Jan; 122(1):144-57. PubMed ID: 22183634
[TBL] [Abstract][Full Text] [Related]
40. Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod.
Berrong Z; Mkrtichyan M; Ahmad S; Webb M; Mohamed E; Okoev G; Matevosyan A; Shrimali R; Abu Eid R; Hammond S; Janik JE; Khleif SN
Cancer Immunol Res; 2018 Feb; 6(2):201-208. PubMed ID: 29305519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
